Laboratorio Elea Phoenix S.A.

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
RacotumomabNo recent activity
Phase 3
NeuGcGM3 gangliosideMonoclonal antibody
Non-Small Cell Lung Cancer
Phase 2
cannabinoidSmall molecule
Parkinson's DiseaseDravet SyndromeLennox-Gastaut Syndrome

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.